Endogena Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Endogena Therapeutics is a private, clinical-stage biotechnology company based in Basel, Switzerland, founded in 2013. The company has developed a proprietary drug discovery platform aimed at identifying small molecules that can stimulate endogenous tissue repair by selectively regulating adult stem and progenitor cells. Its most advanced program is a Phase I/IIa clinical trial for retinitis pigmentosa (RP), which has received FDA Orphan Drug Designation and Fast Track status, with preliminary efficacy data presented in 2024. The pipeline also includes preclinical programs for geographic atrophy (dry AMD) and idiopathic pulmonary fibrosis (IPF).

OphthalmologyPulmonologyRegenerative Medicine

Technology Platform

Proprietary drug discovery platform for identifying small molecules that selectively activate endogenous adult stem and progenitor cells to achieve controlled tissue repair and regeneration.

Opportunities

The lead program in retinitis pigmentosa has FDA Fast Track and Orphan Drug Designation, enabling an accelerated path to market.

The platform's application to large, underserved markets like dry age-related macular degeneration represents a multi-billion dollar opportunity.

Success in the clinic could validate the entire endogenous regeneration approach, enabling expansion into numerous other degenerative conditions.

Risk Factors

The core technology of pharmacologically stimulating endogenous stem cells is novel and unproven in late-stage human trials, carrying high biological risk.

As a private, pre-revenue company, Endogena is dependent on raising significant capital to advance its pipeline, creating financial risk.

It faces intense competition in its target indications from gene therapies, cell transplants, and other modalities.

Competitive Landscape

In ophthalmology, Endogena competes with gene therapy companies (e.g., Spark Therapeutics, Regenxbio) and cell therapy developers for retinal diseases. For dry AMD, it faces competition from complement inhibitors (e.g., Syfovre, Izervay) and other regenerative approaches. In IPF, it competes with approved anti-fibrotics (Pirfenidone, Nintedanib) and other novel mechanisms. Endogena's key differentiation is its small-molecule, endogenous repair approach.

More companies in Regenerative Medicine →More companies in Switzerland →